Simulations Plus: Poised for Growth at Upcoming Healthcare Conferences

Simulations Plus, Inc. (SLP), a leading provider of cheminformatics, biosimulation, and medical communications solutions, is set to participate in two prominent healthcare investor conferences in February 2025. The BTIG 12th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference and the Oppenheimer 35th Annual Healthcare Life Sciences Conference present valuable opportunities for the company to showcase its advanced technology, engage with investors, and foster strategic partnerships.



Simulations Plus' CEO, Shawn O'Connor, will host one-on-one meetings with institutional investors at both conferences and participate in a fireside chat at the Oppenheimer event. These interactions will allow the company to present its cutting-edge software and consulting services, which enhance drug discovery, development, research, clinical trial operations, regulatory submissions, and commercialization. By engaging with investors and industry leaders, Simulations Plus aims to attract new investment, secure strategic partnerships, and expand its reach in the biopharma sector.



The company's recent performance and undervalued status present an attractive entry point for investors. With an intrinsic value of $44.90, Simulations Plus is currently trading at a discount, indicating a potential bargain opportunity. Moreover, the company's earnings are expected to double in the coming years, signaling strong future growth potential.

Simulations Plus' participation in these conferences aligns with its broader strategy for growth and expansion in the healthcare and biopharma sectors. By presenting its innovative solutions and engaging with key stakeholders, the company seeks to capitalize on emerging opportunities and solidify its position as a premier provider of advanced software and consulting services.

The global healthcare simulation market is expected to reach between $3.19 and $7.7 billion by 2027, with a compound annual growth rate of 14.6% to 17.8%. This growth is driven by factors such as increased demand for minimally invasive treatments, growing focus on patient safety, and technological advancements. Simulations Plus' participation in these conferences places it at the forefront of this growth, enabling the company to showcase its offerings and attract new investment.

In conclusion, Simulations Plus' upcoming presentations at the BTIG and Oppenheimer conferences present valuable opportunities for the company to engage with investors, foster strategic partnerships, and solidify its position in the growing healthcare simulation market. With an undervalued status and strong future growth prospects, the company offers an attractive investment opportunity for those seeking exposure to the biopharma sector. As the company continues to innovate and expand its offerings, investors can expect to see further growth and value creation in the coming years.